It has come to the attention of Orion Corporation that the prosecutor has appealed the district court’s decision to dismiss the charges pressed against Ari Lehtoranta, a member of Orion’s Board of Directors, in a securities markets case concerning suspected disclosure offence.
According to Orion’s knowledge, the matter was related to Mr. Lehtoranta’s operations as the CEO of Nokian Tyres plc in 2015-2016. Orion Corporation disclosed the prosecutor’s decision to press charges in a stock exchange release on 29 October 2020 and the district court’s decision to dismiss the charges in a stock exchange release on 10 June 2022. The suspected offence was not related to Orion. Orion will not comment the matter.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Terhi Ormio
Vice President, Communications
Tel. +358 50 966 4646
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
